Two Doses of BNT162b2 Vaccine Protect Against MIS-C
Two doses of Pfizer-BioNTech vaccine have estimated effectiveness of 91 percent against MIS-C in children aged 12 to 18 years
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.